Related Experiment Video

Updated: May 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

[Current state of oncolytic virotherapy in Japan]

Mikihito Nakamori1, Hiroki Yamaue

  • 1Second Dept. of Surgery, Wakayama Medical University, School of Medicine, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 19, 2013
PubMed

Insights

Oncolytic virotherapy uses cancer-destroying viruses. Advances include preclinical cures, drug acceleration of virus spread, and enhanced immunotherapy, with a Phase 3 trial for melanoma nearing completion.

Area of Science:

  • Oncolytic virotherapy
  • Cancer research
  • Virology

Context:

  • Emerging cancer treatment strategy utilizing replication-competent viruses.
  • Recent progress in preclinical studies and drug development for enhanced viral propagation.
  • Significant clinical advancements, including a Phase 3 trial for metastatic melanoma.

Purpose:

  • To summarize recent advances in oncolytic virotherapy.
  • To highlight key preclinical and clinical milestones.
  • To discuss the potential for new oncolytic viruses in clinical settings.

Summary:

  • Oncolytic virotherapy employs viruses to selectively target and eliminate cancer cells.
  • Key developments include preclinical proof-of-concept for single-shot cures, identification of agents to boost intratumoral virus spread, and strategies to enhance anti-tumor immune responses.
  • A major clinical achievement is the completion of patient accrual for a Phase 3 trial of intratumoral herpes simplex virus (OncoVEX) in metastatic melanoma.

Impact:

  • Accelerated clinical development of oncolytic adenoviruses (OBP-301) for esophageal cancer and oncolytic herpes simplex viruses (G47b) for brain cancer in Japan.
  • Potential for a new wave of oncolytic virus therapies entering clinical practice.
  • Improved therapeutic options for cancer patients through viral-mediated tumor destruction and immunotherapy.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Bacterial Artificial Chromosomes: A Functional Genomics Tool for the Study of Positive-strand RNA Viruses12:20

Bacterial Artificial Chromosomes: A Functional Genomics Tool for the Study of Positive-strand RNA Viruses

Published on: December 29, 2015

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...